In its draft guidelines, which were published online and are still open for consultation, the organization stated that GLP-1 drugs, which was first developed by Novo Nordisk and Eli Lilly, were part of the solution in treating obesity among patients with a body mass index (BMI) of 30 or more, together with proper counselling on lifestyle and behavioural changes.